BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1744 related articles for article (PubMed ID: 21935747)

  • 1. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
    Li CI; Malone KE; Saltzman BS; Daling JR
    Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
    Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
    Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
    Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma?
    Bagaria SP; Shamonki J; Kinnaird M; Ray PS; Giuliano AE
    Ann Surg Oncol; 2011 Jul; 18(7):1845-51. PubMed ID: 21287281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
    Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinicopathologic observation of carcinomas arising in fibroepithelial neoplasms of the breast].
    Yang G; Guo L; Jin H; Li J; Ding H
    Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):437-41. PubMed ID: 25327790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubular carcinoma of the breast: institutional and SEER database analysis supporting a unique classification.
    Romano AM; Wages NA; Smolkin M; Fortune KL; Atkins K; Dillon PM
    Breast Dis; 2015; 35(2):103-11. PubMed ID: 25567000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 8. The dilemma of in situ carcinoma of the breast.
    Fentiman IS
    Int J Clin Pract; 2001 Dec; 55(10):680-3. PubMed ID: 11777293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ.
    Fisher ER; Costantino J; Fisher B; Palekar AS; Paik SM; Suarez CM; Wolmark N
    Cancer; 1996 Oct; 78(7):1403-16. PubMed ID: 8839545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ.
    Fisher ER; Land SR; Fisher B; Mamounas E; Gilarski L; Wolmark N
    Cancer; 2004 Jan; 100(2):238-44. PubMed ID: 14716756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.